GlassScriptPhysician profile
Amit S Tibb
NPI 1811914856
$7,000.12
in general payments reported to CMS, 2019-2025
32 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $485 · 2021: $995 · 2022: $1,167 · 2023: $1,092 · 2024: $958 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,337 · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,337.08 |
| Education | $369.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,916.70 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,641.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $431.28 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $371.45 | 2023-2025 | Opsumit, Uptravi |
| Insmed, INC. | $347.63 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $333.17 | 2020-2025 | |
| Covis Pharma Gmbh | $259.23 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $254.82 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.70 | 2019-2024 | Ofev |
| Viatris Specialty LLC | $166.24 | 2025 | Yupelri |
| Genentech USA, INC. | $156.64 | 2019-2023 | Xolair |
| Philips North America LLC | $131.15 | 2021-2023 | |
| Grifols USA, LLC | $111.28 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $105.95 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $74.54 | 2021-2024 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $70.04 | 2020-2022 | |
| Verona Pharma, INC. | $57.09 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $53.57 | 2024-2025 | Inspire |
| Baxter Healthcare | $41.25 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Masimo Corporation | $36.00 | 2024 | Set and Rainbow Set |
| Novartis Pharmaceuticals Corporation | $31.00 | 2020-2021 | |
| Pulmonx Corporation | $28.03 | 2019 | |
| United Therapeutics Corporation | $23.17 | 2021-2025 | Tyvaso |
| Invivyd INC | $18.48 | 2025 | Pemgarda |
| Vertex Pharmaceuticals Incorporated | $15.00 | 2020 | |
| Pfizer INC. | $14.99 | 2022 | |
| Abbvie INC. | $14.80 | 2022 | |
| Esperion Therapeutics, INC. | $13.50 | 2020 | |
| Sunovion Pharmaceuticals INC. | $13.04 | 2019 | |
| Circassia INC. | $11.29 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Tibb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.